In addition, Amgen has acquired non-exclusive worldwide rights for the development and commercialization of diagnostic products for human use based on the same gene.
According to the terms of the agreement, Human Genome Sciences will receive from Amgen an upfront payment and certain annual fees, as well as development milestone payments and royalties on annual net sales for therapeutic and diagnostic products successfully developed and commercialized using such rights.
“This agreement is one more step in our monetization of Human Genome Sciences assets and in providing access to our technology to those companies who share our goal of developing gene-based therapeutic and diagnostic products for use in the treatment of serious diseases,” said H Thomas Watkins, president and CEO, Human Genome Sciences.